Ocugen, Inc. — Director's Dealing 2014

Dec 10, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2014-12-08

Reporting Person: KIRK RANDAL J (10% Owner)
Reporting Person: INTREXON CORP (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2690570	Indirect

Footnotes

F1: The amount of securities beneficially owned reflects (i) 918,206 shares received upon automatic conversion of a Convertible Promissory Note in connection with the issuer's initial public offering and (ii) 1,772,364 shares purchased in the issuer's initial public offering.

F2: Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon Corporation. Shares held by Intrexon Corporation may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial
ownership of such shares, except to the extent of any pecuniary interest therein.